Investigational drug · Phase 2
BMS-986368
Also called: CC-97489
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Agitation, Alzheimer Disease, Multiple Sclerosis Spasticity.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
9
Any phase or sponsor naming "BMS-986368"
First trial start
2025
Jun 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-986368", any sponsor or status.
Conditions studied
As listed on its trial records.
- Agitation
- Alzheimer Disease
- Multiple Sclerosis Spasticity
Approved drugs for the same conditions: Alzheimer's disease · Multiple sclerosis · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-986368" as an intervention, largest first.
- A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityPivotal-lookingRecruiting
CelgeneBristol Myers Squibb (BMY)
NCT06782490 · 200 participants (planned) · Start Jun 5, 2025 · Primary completion May 26, 2027
Drug: BMS-986368; Placebo · For: Multiple Sclerosis Spasticity
Sites: Birmingham, Alabama; Scottsdale, Arizona; Aurora, Colorado · 61 sites in all
- Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseasePivotal-lookingRecruiting
CelgeneBristol Myers Squibb (BMY)
NCT06808984 · 120 participants (planned) · Start Jun 9, 2025 · Primary completion Nov 26, 2027
Drug: BMS-986368; Placebo · For: Agitation; Alzheimer Disease
Sites: Homewood, Alabama; Huntsville, Alabama; Phoenix, Arizona · 77 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT05099822 · 84 participants · Start Mar 13, 2020 · Primary completion Jul 11, 2022
Drug: CC-97489 · For: Healthy Volunteers
Sites: Leuven, Belgium
CelgeneBristol Myers Squibb (BMY)
NCT06411730 · 56 participants · Start May 31, 2024 · Primary completion Oct 28, 2024
Drug: BMS-986368 · For: Healthy Participants
Sites: Anaheim, California
Alberto EsquenaziAcademic, hospital or other
NCT07704840 · 42 participants (planned) · Start Sep 2, 2026 · Primary completion Jun 2027
Drug: Administration of BMS-986368; Placebo · For: Post-Stroke Spasticity
Sites: Elkins Park, Pennsylvania
CelgeneBristol Myers Squibb (BMY)
NCT06170723 · 32 participants · Start Mar 18, 2024 · Primary completion May 25, 2024
Drug: BMS-986368; Itraconazole and 1 more · For: Healthy Participants
Sites: Tempe, Arizona
CelgeneBristol Myers Squibb (BMY)
NCT07837115 · 24 participants (planned) · Start Oct 6, 2026 · Primary completion Dec 19, 2026
Drug: Irafamdastat · For: Healthy Volunteers
Sites: Anaheim, California
- A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese ParticipantsNot yet recruiting
CelgeneBristol Myers Squibb (BMY)
NCT07700329 · 16 participants (planned) · Start Jan 5, 2027 · Primary completion Feb 23, 2027
Drug: BMS-986368 · For: Healthy Volunteers
CelgeneBristol Myers Squibb (BMY)
NCT06227975 · 8 participants · Start Feb 2, 2024 · Primary completion Apr 3, 2024
Drug: [14C]-BMS-986368 · For: Healthy Volunteers
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Agitation
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- AXS-05dextromethorphan-bupropionPhase 33 trials
Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation
- SUVN-502MasupirdinePhase 31 trial
Suven Life Sciences Limited · Agitation, Alzheimer's Type Dementia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.